human interleukin 12 rhil 12 (Neumedicines Inc)
86
Structured Review
Neumedicines Inc
human interleukin 12 rhil 12
Human Interleukin 12 Rhil 12, supplied by Neumedicines Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil+12/12+12+human+interleukin+rhil/us12655159-798-5-11
Average 86 stars, based on 1 article reviews
Human Interleukin 12 Rhil 12, supplied by Neumedicines Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil+12/12+12+human+interleukin+rhil/us12655159-798-5-11
Average 86 stars, based on 1 article reviews
human interleukin 12 rhil 12 - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: CRBN ligands and uses thereof Article Snippet: Other immuno-oncology agents that may be used in the present invention include urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CD137 monoclonal antibody; varlilumab (CDX-1127, Celldex Therapeutics), an anti-CD27 monoclonal antibody; BMS-986178 (Bristol-Myers Squibb), an anti-OX40 monoclonal antibody; lirilumab (IPH2102/BMS-986015, Innate Pharma, Bristol-Myers Squibb), an anti-KIR monoclonal antibody; monalizumab (IPH2201, Innate Pharma, AstraZeneca) an anti-NKG2A monoclonal antibody; andecaliximab (GS-5745, Gilead Sciences), an anti-MMP9 antibody; MK-4166 (Merck & Co.), an anti-GITR monoclonal antibody. Article Title: 1,2-diaminobenzimidazole derivative Article Snippet: In some embodiments, an IL-15 based immunotherapeutic is heterodimeric IL-15 (hetIL-15, Novartis/Admune), a fusion complex composed of a synthetic form of endogenous IL-15 complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL15:sIL-15RA), which has been tested in Phase 1 clinical trials for melanoma, renal cell carcinoma, non-small cell lung cancer and head and neck squamous cell carcinoma (NCT02452268). Article Title: EIF4E inhibitors and uses thereof Article Snippet: In some embodiments, an immunostimulatory therapeutic is recombinant human interleukin 15 (rhIL-15). Article Title: Deuterated IRAK degraders and uses thereof Article Snippet: In some embodiments, an immunostimulatory therapeutic is recombinant human interleukin 15 (rhIL-15). Article Title: GPR84 antagonists and uses thereof Article Snippet: In some embodiments, a recombinant human interleukin 12 (rhIL-12) is Article Title: Antiproliferation compounds and uses thereof Article Snippet: Another immunostimulatory therapeutic that may be used in the present invention is recombinant human interleukin 15 (rhIL-15). Article Title: SMARCA degraders and uses thereof Article Snippet: In some embodiments, a recombinant human interleukin 12 (rhIL-12) is Recombinant:Article Title: Antiproliferation compounds and uses thereof Article Snippet: Another suitable IL-15 based immunotherapeutic is heterodimeric IL-15 (hetIL-15, Novartis/Admune), a fusion complex composed of a synthetic form of endogenous IL-15 complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL15:sIL-15RA), which has been tested in Phase 1 clinical trials for melanoma, renal cell carcinoma, non-small cell lung cancer and head and neck squamous cell carcinoma (NCT02452268). .. Recombinant human interleukin 12 (rhIL-12) has been tested in the clinic for many oncological indications, for example, as a |